Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Teva Inks Biggest Deal in Israeli Pharmaceutical Industry’s History
Error: Contact form not found.
by JNS.org
A Teva factory in Kfar Saba, Israel. The company finalized an acquisition for $40.5 billion. Photo: Wikimedia Commons.
JNS.org – Israeli pharmaceutical giant Teva announced Tuesday that it has finalized its acquisition of Dublin-based Allergan’s Actavis Global Generics for $40.5 billion. This is the biggest acquisition deal in the Israeli pharmaceutical industry’s history.
As part of the deal, Teva Pharmaceutical Industries acquired Actavis Global Generics’ with its US and international generic commercial units, third-party supplier Medis, global generic manufacturing operations, and the global generic research and development unit as well as Allergan’s international over-the-counter commercial unit and certain established international brands, an Allergan press release said.
Allergan is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
The deal means Teva will have 338 products awaiting FDA approval, including 115 products with a first-submit option — a substantial commercial advantage in the global pharmaceutical industry.
Teva recently released a study showing the generic drugs it produces generated savings of about $215 billion to the US healthcare system over the last decade.
“The acquisition of Actavis Global Generics will help us build a new Teva, one with a more solid foundation, upgraded financial profile and more diverse revenue and profit sources,” Teva President and CEO Erez Vigodman said.
